Divisão de Farmacologia, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Clin Pharmacol Ther. 2010 Apr;87(4):417-20. doi: 10.1038/clpt.2009.307. Epub 2010 Feb 24.
There is controversy regarding the association between the CYP4F2 rs2108622 (V33M) polymorphism and warfarin dose requirement in white patients, and there are no data for nonwhite populations. We observed no association in self-identified white, black, or "intermediate" Brazilian patients (n = 370). The addition of the rs2108622 genotype as a variable has only a marginal effect on the predictive power of a warfarin dosing algorithm derived from this patient cohort. We conclude that prospective CYP4F2 genotyping is not justified in Brazilians who are potential candidates for warfarin therapy.
关于 CYP4F2 rs2108622（V33M）多态性与华法林剂量需求之间的关联，在白人患者中存在争议，而对于非白人人群则没有数据。我们在自我认定的白人、黑人和“中间”巴西患者（n = 370）中没有观察到关联。将 rs2108622 基因型作为一个变量添加，仅对从该患者队列得出的华法林剂量算法的预测能力有微小影响。我们的结论是，对于可能接受华法林治疗的巴西人，前瞻性 CYP4F2 基因分型没有理由。
